highly significantp < 0.005
injections of 0.5 mg of mAb anti-CD5, CD20, CD71 or anti-HLA-DR, at 24 and 96 h after grafting, showed highly significant (p < 0.005) improvement of survival (Figure 2 and Table 2 ).
injections of 0.5 mg of mAb anti-CD5, CD20, CD71 or anti-HLA-DR, at 24 and 96 h after grafting, showed highly significant (p < 0.005) improvement of survival (Figure 2 and Table 2 ).